nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—ABCG2—Cladribine—multiple sclerosis	0.0952	0.139	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—multiple sclerosis	0.0704	0.103	CbGbCtD
Ezetimibe—ABCG2—Mitoxantrone—multiple sclerosis	0.0694	0.101	CbGbCtD
Ezetimibe—ABCC2—Dexamethasone—multiple sclerosis	0.0398	0.0581	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—multiple sclerosis	0.0364	0.0531	CbGbCtD
Ezetimibe—ABCG2—Dexamethasone—multiple sclerosis	0.036	0.0525	CbGbCtD
Ezetimibe—ABCB1—Methylprednisolone—multiple sclerosis	0.0343	0.05	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—multiple sclerosis	0.032	0.0467	CbGbCtD
Ezetimibe—CYP3A4—Fingolimod—multiple sclerosis	0.0319	0.0465	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—multiple sclerosis	0.0289	0.0422	CbGbCtD
Ezetimibe—ABCB1—Mitoxantrone—multiple sclerosis	0.025	0.0365	CbGbCtD
Ezetimibe—ABCB1—Betamethasone—multiple sclerosis	0.0223	0.0325	CbGbCtD
Ezetimibe—ABCB1—Prednisolone—multiple sclerosis	0.022	0.0321	CbGbCtD
Ezetimibe—ABCB1—Prednisone—multiple sclerosis	0.0208	0.0303	CbGbCtD
Ezetimibe—CYP3A4—Methylprednisolone—multiple sclerosis	0.0206	0.03	CbGbCtD
Ezetimibe—CYP3A4—Triamcinolone—multiple sclerosis	0.0156	0.0227	CbGbCtD
Ezetimibe—CYP3A4—Mitoxantrone—multiple sclerosis	0.015	0.0219	CbGbCtD
Ezetimibe—CYP3A4—Betamethasone—multiple sclerosis	0.0134	0.0195	CbGbCtD
Ezetimibe—CYP3A4—Prednisolone—multiple sclerosis	0.0132	0.0192	CbGbCtD
Ezetimibe—ABCB1—Dexamethasone—multiple sclerosis	0.013	0.0189	CbGbCtD
Ezetimibe—CYP3A4—Prednisone—multiple sclerosis	0.0125	0.0182	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—multiple sclerosis	0.0104	0.0152	CbGbCtD
Ezetimibe—CYP3A4—Dexamethasone—multiple sclerosis	0.00778	0.0113	CbGbCtD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000395	0.00365	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000395	0.00365	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—MYC—multiple sclerosis	0.000393	0.00363	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000382	0.00353	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.000382	0.00353	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000381	0.00352	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—GPC5—multiple sclerosis	0.000378	0.0035	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000377	0.00348	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000377	0.00348	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—PABPC1—multiple sclerosis	0.000373	0.00345	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000367	0.00339	CbGpPWpGaD
Ezetimibe—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000365	0.00338	CbGpPWpGaD
Ezetimibe—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00035	0.00323	CbGpPWpGaD
Ezetimibe—ABCC3—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000337	0.00311	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—RPL5—multiple sclerosis	0.000336	0.00311	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—RRM1—multiple sclerosis	0.000313	0.0029	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CYP27B1—multiple sclerosis	0.000313	0.0029	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CYP24A1—multiple sclerosis	0.000313	0.0029	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000306	0.00283	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CYP27B1—multiple sclerosis	0.000302	0.00279	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CYP24A1—multiple sclerosis	0.000302	0.00279	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000297	0.00275	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000295	0.00273	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—GPC5—multiple sclerosis	0.000287	0.00265	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000278	0.00257	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—GPC5—multiple sclerosis	0.000276	0.00255	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000271	0.0025	CbGpPWpGaD
Ezetimibe—Malaise—Methylprednisolone—multiple sclerosis	0.000267	0.0013	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000265	0.00245	CbGpPWpGaD
Ezetimibe—Connective tissue disorder—Prednisone—multiple sclerosis	0.000265	0.00129	CcSEcCtD
Ezetimibe—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000265	0.00129	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000264	0.00244	CbGpPWpGaD
Ezetimibe—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000264	0.00128	CcSEcCtD
Ezetimibe—Dizziness—Azathioprine—multiple sclerosis	0.000263	0.00128	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000263	0.00128	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000262	0.00127	CcSEcCtD
Ezetimibe—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000259	0.00126	CcSEcCtD
Ezetimibe—Cough—Triamcinolone—multiple sclerosis	0.000259	0.00126	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000257	0.00125	CcSEcCtD
Ezetimibe—Hypertension—Triamcinolone—multiple sclerosis	0.000256	0.00125	CcSEcCtD
Ezetimibe—Hypertension—Methylprednisolone—multiple sclerosis	0.000256	0.00124	CcSEcCtD
Ezetimibe—Urticaria—Mitoxantrone—multiple sclerosis	0.000255	0.00124	CcSEcCtD
Ezetimibe—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000254	0.00123	CcSEcCtD
Ezetimibe—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000254	0.00123	CcSEcCtD
Ezetimibe—Myalgia—Triamcinolone—multiple sclerosis	0.000253	0.00123	CcSEcCtD
Ezetimibe—Vomiting—Azathioprine—multiple sclerosis	0.000253	0.00123	CcSEcCtD
Ezetimibe—Arthralgia—Methylprednisolone—multiple sclerosis	0.000252	0.00123	CcSEcCtD
Ezetimibe—Myalgia—Methylprednisolone—multiple sclerosis	0.000252	0.00123	CcSEcCtD
Ezetimibe—Infestation NOS—Methotrexate—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Ezetimibe—Infestation—Methotrexate—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Ezetimibe—SLCO1B1—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000251	0.00232	CbGpPWpGaD
Ezetimibe—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000251	0.00232	CbGpPWpGaD
Ezetimibe—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000251	0.00232	CbGpPWpGaD
Ezetimibe—Rash—Azathioprine—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—SRM—multiple sclerosis	0.000251	0.00232	CbGpPWpGaD
Ezetimibe—Dermatitis—Azathioprine—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Ezetimibe—Flushing—Prednisone—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Ezetimibe—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Ezetimibe—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Ezetimibe—Discomfort—Triamcinolone—multiple sclerosis	0.00025	0.00121	CcSEcCtD
Ezetimibe—Discomfort—Methylprednisolone—multiple sclerosis	0.000249	0.00121	CcSEcCtD
Ezetimibe—Headache—Azathioprine—multiple sclerosis	0.000249	0.00121	CcSEcCtD
Ezetimibe—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000247	0.00229	CbGpPWpGaD
Ezetimibe—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000247	0.00229	CbGpPWpGaD
Ezetimibe—Dry mouth—Triamcinolone—multiple sclerosis	0.000247	0.0012	CcSEcCtD
Ezetimibe—Angioedema—Dexamethasone—multiple sclerosis	0.000246	0.0012	CcSEcCtD
Ezetimibe—Angioedema—Betamethasone—multiple sclerosis	0.000246	0.0012	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—BCHE—multiple sclerosis	0.000246	0.00227	CbGpPWpGaD
Ezetimibe—Angiopathy—Prednisone—multiple sclerosis	0.000245	0.00119	CcSEcCtD
Ezetimibe—Confusional state—Methylprednisolone—multiple sclerosis	0.000244	0.00119	CcSEcCtD
Ezetimibe—Immune system disorder—Prednisone—multiple sclerosis	0.000244	0.00118	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000243	0.00225	CbGpPWpGaD
Ezetimibe—Malaise—Betamethasone—multiple sclerosis	0.000243	0.00118	CcSEcCtD
Ezetimibe—Malaise—Dexamethasone—multiple sclerosis	0.000243	0.00118	CcSEcCtD
Ezetimibe—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000242	0.00118	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000242	0.00118	CcSEcCtD
Ezetimibe—Infection—Triamcinolone—multiple sclerosis	0.000241	0.00117	CcSEcCtD
Ezetimibe—Infection—Methylprednisolone—multiple sclerosis	0.00024	0.00117	CcSEcCtD
Ezetimibe—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.00024	0.00222	CbGpPWpGaD
Ezetimibe—Insomnia—Prednisolone—multiple sclerosis	0.000238	0.00116	CcSEcCtD
Ezetimibe—Alopecia—Prednisone—multiple sclerosis	0.000238	0.00116	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—RRM1—multiple sclerosis	0.000237	0.0022	CbGpPWpGaD
Ezetimibe—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000237	0.00115	CcSEcCtD
Ezetimibe—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000237	0.00115	CcSEcCtD
Ezetimibe—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000237	0.00115	CcSEcCtD
Ezetimibe—Paraesthesia—Prednisolone—multiple sclerosis	0.000237	0.00115	CcSEcCtD
Ezetimibe—Mental disorder—Prednisone—multiple sclerosis	0.000236	0.00115	CcSEcCtD
Ezetimibe—Nausea—Azathioprine—multiple sclerosis	0.000236	0.00115	CcSEcCtD
Ezetimibe—Skin disorder—Methylprednisolone—multiple sclerosis	0.000235	0.00114	CcSEcCtD
Ezetimibe—Malnutrition—Prednisone—multiple sclerosis	0.000235	0.00114	CcSEcCtD
Ezetimibe—Erythema—Prednisone—multiple sclerosis	0.000235	0.00114	CcSEcCtD
Ezetimibe—Hypertension—Betamethasone—multiple sclerosis	0.000233	0.00113	CcSEcCtD
Ezetimibe—Hypertension—Dexamethasone—multiple sclerosis	0.000233	0.00113	CcSEcCtD
Ezetimibe—UGT2B15—Biological oxidations—POMC—multiple sclerosis	0.000232	0.00215	CbGpPWpGaD
Ezetimibe—Asthenia—Mitoxantrone—multiple sclerosis	0.000231	0.00112	CcSEcCtD
Ezetimibe—Myalgia—Betamethasone—multiple sclerosis	0.000229	0.00112	CcSEcCtD
Ezetimibe—Myalgia—Dexamethasone—multiple sclerosis	0.000229	0.00112	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—RRM1—multiple sclerosis	0.000229	0.00211	CbGpPWpGaD
Ezetimibe—Discomfort—Betamethasone—multiple sclerosis	0.000227	0.0011	CcSEcCtD
Ezetimibe—Discomfort—Dexamethasone—multiple sclerosis	0.000227	0.0011	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000226	0.00209	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000226	0.00209	CbGpPWpGaD
Ezetimibe—Pain—Prednisolone—multiple sclerosis	0.000225	0.0011	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—multiple sclerosis	0.000225	0.00109	CcSEcCtD
Ezetimibe—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000225	0.00208	CbGpPWpGaD
Ezetimibe—Pharyngitis—Methotrexate—multiple sclerosis	0.000224	0.00109	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000221	0.00107	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00022	0.00107	CcSEcCtD
Ezetimibe—Anaphylactic shock—Betamethasone—multiple sclerosis	0.00022	0.00107	CcSEcCtD
Ezetimibe—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.00022	0.00107	CcSEcCtD
Ezetimibe—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00022	0.00107	CcSEcCtD
Ezetimibe—Insomnia—Triamcinolone—multiple sclerosis	0.000219	0.00107	CcSEcCtD
Ezetimibe—Insomnia—Methylprednisolone—multiple sclerosis	0.000219	0.00106	CcSEcCtD
Ezetimibe—Infection—Betamethasone—multiple sclerosis	0.000219	0.00106	CcSEcCtD
Ezetimibe—Infection—Dexamethasone—multiple sclerosis	0.000219	0.00106	CcSEcCtD
Ezetimibe—Ill-defined disorder—Prednisone—multiple sclerosis	0.000218	0.00106	CcSEcCtD
Ezetimibe—Paraesthesia—Triamcinolone—multiple sclerosis	0.000218	0.00106	CcSEcCtD
Ezetimibe—Feeling abnormal—Prednisolone—multiple sclerosis	0.000217	0.00106	CcSEcCtD
Ezetimibe—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000217	0.00106	CcSEcCtD
Ezetimibe—Anaemia—Prednisone—multiple sclerosis	0.000217	0.00105	CcSEcCtD
Ezetimibe—Dyspnoea—Triamcinolone—multiple sclerosis	0.000216	0.00105	CcSEcCtD
Ezetimibe—Nervous system disorder—Betamethasone—multiple sclerosis	0.000216	0.00105	CcSEcCtD
Ezetimibe—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000216	0.00105	CcSEcCtD
Ezetimibe—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000215	0.00105	CcSEcCtD
Ezetimibe—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000215	0.00105	CcSEcCtD
Ezetimibe—Angioedema—Prednisone—multiple sclerosis	0.000214	0.00104	CcSEcCtD
Ezetimibe—Dyspepsia—Triamcinolone—multiple sclerosis	0.000213	0.00104	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—multiple sclerosis	0.000213	0.00104	CcSEcCtD
Ezetimibe—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000213	0.00103	CcSEcCtD
Ezetimibe—Malaise—Prednisone—multiple sclerosis	0.000212	0.00103	CcSEcCtD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00021	0.00194	CbGpPWpGaD
Ezetimibe—Urticaria—Prednisolone—multiple sclerosis	0.000209	0.00102	CcSEcCtD
Ezetimibe—Fatigue—Triamcinolone—multiple sclerosis	0.000209	0.00102	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000209	0.00193	CbGpPWpGaD
Ezetimibe—Fatigue—Methylprednisolone—multiple sclerosis	0.000209	0.00101	CcSEcCtD
Ezetimibe—Pain—Triamcinolone—multiple sclerosis	0.000207	0.00101	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000206	0.0019	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000206	0.0019	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000205	0.0019	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000205	0.0019	CbGpPWpGaD
Ezetimibe—Angiopathy—Methotrexate—multiple sclerosis	0.000204	0.000993	CcSEcCtD
Ezetimibe—Vomiting—Mitoxantrone—multiple sclerosis	0.000204	0.000993	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—multiple sclerosis	0.000204	0.000989	CcSEcCtD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000203	0.00188	CbGpPWpGaD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000203	0.00188	CbGpPWpGaD
Ezetimibe—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000203	0.000987	CcSEcCtD
Ezetimibe—Hypertension—Prednisone—multiple sclerosis	0.000203	0.000985	CcSEcCtD
Ezetimibe—Rash—Mitoxantrone—multiple sclerosis	0.000203	0.000984	CcSEcCtD
Ezetimibe—Dermatitis—Mitoxantrone—multiple sclerosis	0.000202	0.000984	CcSEcCtD
Ezetimibe—Headache—Mitoxantrone—multiple sclerosis	0.000201	0.000978	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.0002	0.000974	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.0002	0.000974	CcSEcCtD
Ezetimibe—Arthralgia—Prednisone—multiple sclerosis	0.0002	0.000971	CcSEcCtD
Ezetimibe—Myalgia—Prednisone—multiple sclerosis	0.0002	0.000971	CcSEcCtD
Ezetimibe—Feeling abnormal—Triamcinolone—multiple sclerosis	0.0002	0.000971	CcSEcCtD
Ezetimibe—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000199	0.000969	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—multiple sclerosis	0.000199	0.000968	CcSEcCtD
Ezetimibe—Insomnia—Betamethasone—multiple sclerosis	0.000199	0.000967	CcSEcCtD
Ezetimibe—Insomnia—Dexamethasone—multiple sclerosis	0.000199	0.000967	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000198	0.000964	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000198	0.000961	CcSEcCtD
Ezetimibe—Paraesthesia—Betamethasone—multiple sclerosis	0.000198	0.00096	CcSEcCtD
Ezetimibe—Paraesthesia—Dexamethasone—multiple sclerosis	0.000198	0.00096	CcSEcCtD
Ezetimibe—Discomfort—Prednisone—multiple sclerosis	0.000197	0.000959	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—multiple sclerosis	0.000197	0.000959	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—multiple sclerosis	0.000196	0.000953	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—multiple sclerosis	0.000196	0.000953	CcSEcCtD
Ezetimibe—Hypersensitivity—Prednisolone—multiple sclerosis	0.000194	0.000944	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000194	0.0018	CbGpPWpGaD
Ezetimibe—Dyspepsia—Dexamethasone—multiple sclerosis	0.000194	0.000941	CcSEcCtD
Ezetimibe—Dyspepsia—Betamethasone—multiple sclerosis	0.000194	0.000941	CcSEcCtD
Ezetimibe—Urticaria—Triamcinolone—multiple sclerosis	0.000193	0.000936	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000192	0.00178	CbGpPWpGaD
Ezetimibe—Urticaria—Methylprednisolone—multiple sclerosis	0.000192	0.000934	CcSEcCtD
Ezetimibe—Body temperature increased—Triamcinolone—multiple sclerosis	0.000192	0.000931	CcSEcCtD
Ezetimibe—Anaphylactic shock—Prednisone—multiple sclerosis	0.000192	0.000931	CcSEcCtD
Ezetimibe—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000191	0.000929	CcSEcCtD
Ezetimibe—Decreased appetite—Betamethasone—multiple sclerosis	0.000191	0.000929	CcSEcCtD
Ezetimibe—Decreased appetite—Dexamethasone—multiple sclerosis	0.000191	0.000929	CcSEcCtD
Ezetimibe—Nausea—Mitoxantrone—multiple sclerosis	0.000191	0.000927	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.00019	0.00176	CbGpPWpGaD
Ezetimibe—Infection—Prednisone—multiple sclerosis	0.00019	0.000925	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00019	0.000923	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00019	0.000923	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—multiple sclerosis	0.00019	0.000922	CcSEcCtD
Ezetimibe—Fatigue—Dexamethasone—multiple sclerosis	0.00019	0.000922	CcSEcCtD
Ezetimibe—Fatigue—Betamethasone—multiple sclerosis	0.00019	0.000922	CcSEcCtD
Ezetimibe—Pain—Betamethasone—multiple sclerosis	0.000188	0.000914	CcSEcCtD
Ezetimibe—Pain—Dexamethasone—multiple sclerosis	0.000188	0.000914	CcSEcCtD
Ezetimibe—Nervous system disorder—Prednisone—multiple sclerosis	0.000188	0.000913	CcSEcCtD
Ezetimibe—Skin disorder—Prednisone—multiple sclerosis	0.000186	0.000904	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000185	0.00171	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000184	0.0017	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000183	0.00169	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000182	0.00169	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000182	0.000884	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—multiple sclerosis	0.000181	0.000881	CcSEcCtD
Ezetimibe—Feeling abnormal—Betamethasone—multiple sclerosis	0.000181	0.000881	CcSEcCtD
Ezetimibe—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000181	0.000881	CcSEcCtD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000181	0.00167	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000181	0.00167	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—BCHE—multiple sclerosis	0.00018	0.00166	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00018	0.000874	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00018	0.000874	CcSEcCtD
Ezetimibe—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000179	0.000868	CcSEcCtD
Ezetimibe—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000178	0.000866	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000177	0.00164	CbGpPWpGaD
Ezetimibe—Malaise—Methotrexate—multiple sclerosis	0.000177	0.00086	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—CYP24A1—multiple sclerosis	0.000176	0.00163	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CYP27B1—multiple sclerosis	0.000176	0.00163	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000176	0.00163	CbGpPWpGaD
Ezetimibe—Urticaria—Betamethasone—multiple sclerosis	0.000175	0.000849	CcSEcCtD
Ezetimibe—Urticaria—Dexamethasone—multiple sclerosis	0.000175	0.000849	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000175	0.000848	CcSEcCtD
Ezetimibe—Dizziness—Prednisolone—multiple sclerosis	0.000174	0.000847	CcSEcCtD
Ezetimibe—Asthenia—Triamcinolone—multiple sclerosis	0.000174	0.000845	CcSEcCtD
Ezetimibe—Abdominal pain—Dexamethasone—multiple sclerosis	0.000174	0.000845	CcSEcCtD
Ezetimibe—Body temperature increased—Betamethasone—multiple sclerosis	0.000174	0.000845	CcSEcCtD
Ezetimibe—Body temperature increased—Dexamethasone—multiple sclerosis	0.000174	0.000845	CcSEcCtD
Ezetimibe—Abdominal pain—Betamethasone—multiple sclerosis	0.000174	0.000845	CcSEcCtD
Ezetimibe—Asthenia—Methylprednisolone—multiple sclerosis	0.000174	0.000843	CcSEcCtD
Ezetimibe—Insomnia—Prednisone—multiple sclerosis	0.000173	0.000842	CcSEcCtD
Ezetimibe—Paraesthesia—Prednisone—multiple sclerosis	0.000172	0.000836	CcSEcCtD
Ezetimibe—Pruritus—Triamcinolone—multiple sclerosis	0.000172	0.000833	CcSEcCtD
Ezetimibe—Cough—Methotrexate—multiple sclerosis	0.000171	0.000832	CcSEcCtD
Ezetimibe—Pruritus—Methylprednisolone—multiple sclerosis	0.000171	0.000832	CcSEcCtD
Ezetimibe—Dyspepsia—Prednisone—multiple sclerosis	0.000169	0.000819	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—multiple sclerosis	0.000167	0.000812	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—multiple sclerosis	0.000167	0.000812	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—multiple sclerosis	0.000167	0.000812	CcSEcCtD
Ezetimibe—Decreased appetite—Prednisone—multiple sclerosis	0.000167	0.000809	CcSEcCtD
Ezetimibe—Rash—Prednisolone—multiple sclerosis	0.000166	0.000808	CcSEcCtD
Ezetimibe—Dermatitis—Prednisolone—multiple sclerosis	0.000166	0.000807	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000166	0.000806	CcSEcCtD
Ezetimibe—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000166	0.000804	CcSEcCtD
Ezetimibe—Fatigue—Prednisone—multiple sclerosis	0.000165	0.000803	CcSEcCtD
Ezetimibe—Headache—Prednisolone—multiple sclerosis	0.000165	0.000802	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—multiple sclerosis	0.000165	0.000802	CcSEcCtD
Ezetimibe—Constipation—Prednisone—multiple sclerosis	0.000164	0.000796	CcSEcCtD
Ezetimibe—Confusional state—Methotrexate—multiple sclerosis	0.000161	0.000784	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—GPC5—multiple sclerosis	0.000161	0.00149	CbGpPWpGaD
Ezetimibe—Dizziness—Triamcinolone—multiple sclerosis	0.00016	0.000779	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methotrexate—multiple sclerosis	0.00016	0.000778	CcSEcCtD
Ezetimibe—Dizziness—Methylprednisolone—multiple sclerosis	0.00016	0.000777	CcSEcCtD
Ezetimibe—Infection—Methotrexate—multiple sclerosis	0.000159	0.000773	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000158	0.00146	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Prednisone—multiple sclerosis	0.000158	0.000767	CcSEcCtD
Ezetimibe—Asthenia—Betamethasone—multiple sclerosis	0.000158	0.000767	CcSEcCtD
Ezetimibe—Asthenia—Dexamethasone—multiple sclerosis	0.000158	0.000767	CcSEcCtD
Ezetimibe—Nervous system disorder—Methotrexate—multiple sclerosis	0.000157	0.000763	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000157	0.000762	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000157	0.000761	CcSEcCtD
Ezetimibe—Nausea—Prednisolone—multiple sclerosis	0.000157	0.000761	CcSEcCtD
Ezetimibe—Pruritus—Betamethasone—multiple sclerosis	0.000156	0.000756	CcSEcCtD
Ezetimibe—Pruritus—Dexamethasone—multiple sclerosis	0.000156	0.000756	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—multiple sclerosis	0.000156	0.000756	CcSEcCtD
Ezetimibe—Vomiting—Triamcinolone—multiple sclerosis	0.000154	0.000749	CcSEcCtD
Ezetimibe—Vomiting—Methylprednisolone—multiple sclerosis	0.000154	0.000747	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000153	0.00141	CbGpPWpGaD
Ezetimibe—Rash—Triamcinolone—multiple sclerosis	0.000153	0.000743	CcSEcCtD
Ezetimibe—Dermatitis—Triamcinolone—multiple sclerosis	0.000153	0.000742	CcSEcCtD
Ezetimibe—Rash—Methylprednisolone—multiple sclerosis	0.000153	0.000741	CcSEcCtD
Ezetimibe—Dermatitis—Methylprednisolone—multiple sclerosis	0.000152	0.00074	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000152	0.00141	CbGpPWpGaD
Ezetimibe—Urticaria—Prednisone—multiple sclerosis	0.000152	0.000739	CcSEcCtD
Ezetimibe—Headache—Triamcinolone—multiple sclerosis	0.000152	0.000738	CcSEcCtD
Ezetimibe—Headache—Methylprednisolone—multiple sclerosis	0.000152	0.000736	CcSEcCtD
Ezetimibe—Abdominal pain—Prednisone—multiple sclerosis	0.000151	0.000736	CcSEcCtD
Ezetimibe—Body temperature increased—Prednisone—multiple sclerosis	0.000151	0.000736	CcSEcCtD
Ezetimibe—Diarrhoea—Dexamethasone—multiple sclerosis	0.000151	0.000731	CcSEcCtD
Ezetimibe—Diarrhoea—Betamethasone—multiple sclerosis	0.000151	0.000731	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000149	0.00137	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000146	0.00135	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000146	0.000709	CcSEcCtD
Ezetimibe—Dizziness—Betamethasone—multiple sclerosis	0.000145	0.000707	CcSEcCtD
Ezetimibe—Dizziness—Dexamethasone—multiple sclerosis	0.000145	0.000707	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—multiple sclerosis	0.000145	0.000704	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000144	0.00133	CbGpPWpGaD
Ezetimibe—Nausea—Triamcinolone—multiple sclerosis	0.000144	0.0007	CcSEcCtD
Ezetimibe—Paraesthesia—Methotrexate—multiple sclerosis	0.000144	0.000699	CcSEcCtD
Ezetimibe—Nausea—Methylprednisolone—multiple sclerosis	0.000144	0.000698	CcSEcCtD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000143	0.00132	CbGpPWpGaD
Ezetimibe—Dyspnoea—Methotrexate—multiple sclerosis	0.000143	0.000694	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000142	0.00132	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000142	0.00131	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Prednisone—multiple sclerosis	0.000141	0.000686	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000141	0.0013	CbGpPWpGaD
Ezetimibe—Dyspepsia—Methotrexate—multiple sclerosis	0.000141	0.000685	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.00014	0.00129	CbGpPWpGaD
Ezetimibe—Vomiting—Betamethasone—multiple sclerosis	0.00014	0.00068	CcSEcCtD
Ezetimibe—Vomiting—Dexamethasone—multiple sclerosis	0.00014	0.00068	CcSEcCtD
Ezetimibe—Decreased appetite—Methotrexate—multiple sclerosis	0.000139	0.000676	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000139	0.00128	CbGpPWpGaD
Ezetimibe—Rash—Dexamethasone—multiple sclerosis	0.000139	0.000674	CcSEcCtD
Ezetimibe—Rash—Betamethasone—multiple sclerosis	0.000139	0.000674	CcSEcCtD
Ezetimibe—Dermatitis—Betamethasone—multiple sclerosis	0.000139	0.000673	CcSEcCtD
Ezetimibe—Dermatitis—Dexamethasone—multiple sclerosis	0.000139	0.000673	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000138	0.000672	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—multiple sclerosis	0.000138	0.000671	CcSEcCtD
Ezetimibe—Headache—Betamethasone—multiple sclerosis	0.000138	0.00067	CcSEcCtD
Ezetimibe—Headache—Dexamethasone—multiple sclerosis	0.000138	0.00067	CcSEcCtD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000137	0.00127	CbGpPWpGaD
Ezetimibe—Asthenia—Prednisone—multiple sclerosis	0.000137	0.000668	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000137	0.00127	CbGpPWpGaD
Ezetimibe—Pain—Methotrexate—multiple sclerosis	0.000137	0.000665	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—BCHE—multiple sclerosis	0.000136	0.00126	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000136	0.00125	CbGpPWpGaD
Ezetimibe—Pruritus—Prednisone—multiple sclerosis	0.000136	0.000659	CcSEcCtD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000134	0.00124	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000134	0.00124	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—SRM—multiple sclerosis	0.000134	0.00124	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—RRM1—multiple sclerosis	0.000134	0.00124	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000134	0.00124	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000133	0.00123	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000132	0.00122	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Methotrexate—multiple sclerosis	0.000132	0.000641	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—BCHE—multiple sclerosis	0.000131	0.00121	CbGpPWpGaD
Ezetimibe—Diarrhoea—Prednisone—multiple sclerosis	0.000131	0.000637	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000131	0.000636	CcSEcCtD
Ezetimibe—Nausea—Dexamethasone—multiple sclerosis	0.000131	0.000635	CcSEcCtD
Ezetimibe—Nausea—Betamethasone—multiple sclerosis	0.000131	0.000635	CcSEcCtD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000129	0.00119	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000127	0.00118	CbGpPWpGaD
Ezetimibe—Urticaria—Methotrexate—multiple sclerosis	0.000127	0.000618	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—POMC—multiple sclerosis	0.000127	0.00118	CbGpPWpGaD
Ezetimibe—Dizziness—Prednisone—multiple sclerosis	0.000127	0.000616	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—multiple sclerosis	0.000127	0.000615	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—multiple sclerosis	0.000127	0.000615	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—CCL2—multiple sclerosis	0.000124	0.00115	CbGpPWpGaD
Ezetimibe—UGT1A3—Biological oxidations—POMC—multiple sclerosis	0.000124	0.00115	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000122	0.00113	CbGpPWpGaD
Ezetimibe—Vomiting—Prednisone—multiple sclerosis	0.000122	0.000592	CcSEcCtD
Ezetimibe—Rash—Prednisone—multiple sclerosis	0.000121	0.000587	CcSEcCtD
Ezetimibe—Dermatitis—Prednisone—multiple sclerosis	0.000121	0.000586	CcSEcCtD
Ezetimibe—Headache—Prednisone—multiple sclerosis	0.00012	0.000583	CcSEcCtD
Ezetimibe—Hypersensitivity—Methotrexate—multiple sclerosis	0.000118	0.000573	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000118	0.00109	CbGpPWpGaD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000115	0.00106	CbGpPWpGaD
Ezetimibe—Asthenia—Methotrexate—multiple sclerosis	0.000115	0.000558	CcSEcCtD
Ezetimibe—ABCC3—Metabolism—SRM—multiple sclerosis	0.000114	0.00105	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—SRM—multiple sclerosis	0.000114	0.00105	CbGpPWpGaD
Ezetimibe—Nausea—Prednisone—multiple sclerosis	0.000114	0.000553	CcSEcCtD
Ezetimibe—Pruritus—Methotrexate—multiple sclerosis	0.000113	0.00055	CcSEcCtD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000111	0.00103	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000111	0.00102	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.00011	0.00102	CbGpPWpGaD
Ezetimibe—Diarrhoea—Methotrexate—multiple sclerosis	0.00011	0.000532	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—APOE—multiple sclerosis	0.000108	0.001	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000108	0.000998	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000108	0.000998	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000106	0.000984	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000106	0.000984	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000106	0.00098	CbGpPWpGaD
Ezetimibe—Dizziness—Methotrexate—multiple sclerosis	0.000106	0.000514	CcSEcCtD
Ezetimibe—UGT2B7—Biological oxidations—POMC—multiple sclerosis	0.000106	0.000978	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000104	0.000963	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000104	0.000961	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000104	0.000961	CbGpPWpGaD
Ezetimibe—Vomiting—Methotrexate—multiple sclerosis	0.000102	0.000495	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000101	0.000935	CbGpPWpGaD
Ezetimibe—Rash—Methotrexate—multiple sclerosis	0.000101	0.000491	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—multiple sclerosis	0.000101	0.00049	CcSEcCtD
Ezetimibe—Headache—Methotrexate—multiple sclerosis	0.0001	0.000487	CcSEcCtD
Ezetimibe—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	9.88e-05	0.000914	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	9.78e-05	0.000904	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.65e-05	0.000892	CbGpPWpGaD
Ezetimibe—Nausea—Methotrexate—multiple sclerosis	9.51e-05	0.000462	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—CYP24A1—multiple sclerosis	9.45e-05	0.000874	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CYP27B1—multiple sclerosis	9.45e-05	0.000874	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—FAS—multiple sclerosis	9.32e-05	0.000861	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—POMC—multiple sclerosis	9.3e-05	0.00086	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—SRM—multiple sclerosis	9.27e-05	0.000857	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	9.26e-05	0.000856	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	9.16e-05	0.000847	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.77e-05	0.000811	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GPC5—multiple sclerosis	8.65e-05	0.000799	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—POMC—multiple sclerosis	8.59e-05	0.000794	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—SRM—multiple sclerosis	8.5e-05	0.000785	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—ALB—multiple sclerosis	8.48e-05	0.000784	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	8.37e-05	0.000774	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.24e-05	0.000761	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—APOE—multiple sclerosis	8.21e-05	0.000759	CbGpPWpGaD
Ezetimibe—UGT1A3—NRF2 pathway—TGFB1—multiple sclerosis	8.18e-05	0.000756	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP27B1—multiple sclerosis	8.04e-05	0.000743	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP24A1—multiple sclerosis	8.04e-05	0.000743	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP27B1—multiple sclerosis	8.04e-05	0.000743	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP24A1—multiple sclerosis	8.04e-05	0.000743	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—APOE—multiple sclerosis	7.9e-05	0.00073	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—SRM—multiple sclerosis	7.87e-05	0.000727	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.86e-05	0.000726	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.75e-05	0.000717	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CD80—multiple sclerosis	7.73e-05	0.000715	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—BCHE—multiple sclerosis	7.68e-05	0.00071	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.63e-05	0.000705	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GPC5—multiple sclerosis	7.35e-05	0.00068	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GPC5—multiple sclerosis	7.35e-05	0.00068	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.28e-05	0.000673	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—RRM1—multiple sclerosis	7.16e-05	0.000662	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—POMC—multiple sclerosis	7.05e-05	0.000652	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—TGFB1—multiple sclerosis	6.95e-05	0.000643	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—TGFB1—multiple sclerosis	6.95e-05	0.000643	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.88e-05	0.000636	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—POMC—multiple sclerosis	6.79e-05	0.000627	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.74e-05	0.000623	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	6.69e-05	0.000619	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP27B1—multiple sclerosis	6.53e-05	0.000604	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP24A1—multiple sclerosis	6.53e-05	0.000604	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—ALB—multiple sclerosis	6.43e-05	0.000594	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	6.22e-05	0.000575	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—ALB—multiple sclerosis	6.19e-05	0.000572	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	6.11e-05	0.000565	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—RRM1—multiple sclerosis	6.09e-05	0.000563	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—RRM1—multiple sclerosis	6.09e-05	0.000563	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP24A1—multiple sclerosis	5.99e-05	0.000553	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP27B1—multiple sclerosis	5.99e-05	0.000553	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GPC5—multiple sclerosis	5.97e-05	0.000552	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.85e-05	0.000541	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—TGFB1—multiple sclerosis	5.65e-05	0.000522	CbGpPWpGaD
Ezetimibe—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.64e-05	0.000521	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP27B1—multiple sclerosis	5.54e-05	0.000512	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP24A1—multiple sclerosis	5.54e-05	0.000512	CbGpPWpGaD
Ezetimibe—ABCC2—NRF2 pathway—TGFB1—multiple sclerosis	5.51e-05	0.00051	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GPC5—multiple sclerosis	5.47e-05	0.000506	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	5.45e-05	0.000504	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL2—multiple sclerosis	5.43e-05	0.000502	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.37e-05	0.000497	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.22e-05	0.000482	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	5.16e-05	0.000477	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GPC5—multiple sclerosis	5.07e-05	0.000469	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—RRM1—multiple sclerosis	4.95e-05	0.000458	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.73e-05	0.000437	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—APOE—multiple sclerosis	4.62e-05	0.000427	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.6e-05	0.000425	CbGpPWpGaD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.57e-05	0.000423	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—RRM1—multiple sclerosis	4.54e-05	0.000419	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—SRM—multiple sclerosis	4.25e-05	0.000393	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	4.24e-05	0.000392	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—RRM1—multiple sclerosis	4.2e-05	0.000388	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.12e-05	0.000381	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—BCHE—multiple sclerosis	4.12e-05	0.00038	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.06e-05	0.000375	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—POMC—multiple sclerosis	3.97e-05	0.000367	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.96e-05	0.000366	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.7e-05	0.000342	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.64e-05	0.000337	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ALB—multiple sclerosis	3.62e-05	0.000335	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.52e-05	0.000325	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.52e-05	0.000325	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—BCHE—multiple sclerosis	3.5e-05	0.000324	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—BCHE—multiple sclerosis	3.5e-05	0.000324	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.02e-05	0.00028	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP24A1—multiple sclerosis	3e-05	0.000277	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP27B1—multiple sclerosis	3e-05	0.000277	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—BCHE—multiple sclerosis	2.84e-05	0.000263	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.79e-05	0.000258	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.76e-05	0.000255	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GPC5—multiple sclerosis	2.74e-05	0.000253	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.62e-05	0.000242	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—SRM—multiple sclerosis	2.62e-05	0.000242	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—BCHE—multiple sclerosis	2.61e-05	0.000241	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—APOE—multiple sclerosis	2.48e-05	0.000229	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.43e-05	0.000225	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.43e-05	0.000224	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—BCHE—multiple sclerosis	2.41e-05	0.000223	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—RRM1—multiple sclerosis	2.27e-05	0.00021	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—POMC—multiple sclerosis	2.13e-05	0.000197	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—APOE—multiple sclerosis	2.1e-05	0.000195	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—APOE—multiple sclerosis	2.1e-05	0.000195	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.1e-05	0.000194	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.09e-05	0.000193	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.05e-05	0.00019	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.95e-05	0.00018	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ALB—multiple sclerosis	1.94e-05	0.000179	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.85e-05	0.000171	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.85e-05	0.000171	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—POMC—multiple sclerosis	1.81e-05	0.000167	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—POMC—multiple sclerosis	1.81e-05	0.000167	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—APOE—multiple sclerosis	1.71e-05	0.000158	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.69e-05	0.000156	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ALB—multiple sclerosis	1.65e-05	0.000152	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ALB—multiple sclerosis	1.65e-05	0.000152	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—APOE—multiple sclerosis	1.57e-05	0.000145	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—POMC—multiple sclerosis	1.47e-05	0.000136	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—APOE—multiple sclerosis	1.45e-05	0.000134	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.4e-05	0.000129	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—POMC—multiple sclerosis	1.35e-05	0.000124	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ALB—multiple sclerosis	1.34e-05	0.000124	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.31e-05	0.000121	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—BCHE—multiple sclerosis	1.3e-05	0.000121	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—POMC—multiple sclerosis	1.25e-05	0.000115	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ALB—multiple sclerosis	1.23e-05	0.000114	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ALB—multiple sclerosis	1.14e-05	0.000105	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.04e-06	7.43e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—APOE—multiple sclerosis	7.85e-06	7.25e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—POMC—multiple sclerosis	6.74e-06	6.23e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ALB—multiple sclerosis	6.15e-06	5.68e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—APOE—multiple sclerosis	4.83e-06	4.47e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—POMC—multiple sclerosis	4.15e-06	3.84e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ALB—multiple sclerosis	3.79e-06	3.5e-05	CbGpPWpGaD
